SITE Centers Corp. SITC
0.67 USD +0.10 (+17.19%)
At closeNov 6, 2026, 7:48 PM EST
0.68 +0.01 +1.62%
After hours · Nov 6, 7:48 PM ET
0.59 Day range 0.7329
0.59 52-week range 7.49
- YTD
- -89.60%
- 1 year
- -90.67%
- Market cap
- 35.07M
- Revenue (ttm)
- 451.68M
- Profit margin
- 162.52%
- EPS (ttm)
- 2.44
- Shares out
- 52.43M
- P/E ratio
- 0.27
- Forward P/E
- -20.68
- Dividend
- 2.08 (13.45%)
- Ex-dividend date
- Jun 17, 2024
- YTD return
- -89.60%
- 1-year return
- -90.67%
- Volume
- 14.96M
- Avg volume
- 1.90M
- Open
- 0.61
- Previous close
- 0.57
- Day's range
- 0.59 – 0.7329
- 52-week range
- 0.59 – 7.49
- Beta
- 1.76
- Analysts
- Hold
- Price target
- 23.75 (+3455.4%)
- Earnings date
- Feb 11, 2025
ALL -25.3420 (-97.43%)
Key statistics
- Enterprise value
- 258.68M
- PEG ratio
- 0.00
- Price / sales
- 1.78
- Price / book
- 0.32
- Dividend yield
- 13.45%
- Payout ratio
- 11.38%
- Revenue growth
- -37.30%
- Free cash flow
- 573.49M
- Total cash
- 1.06B
- Total debt
- 336.66M
- Return on equity
- 31.25%
- Short % of float
- 9.92%
- 50-day average
- 16.04
- 200-day average
- 44.56
Analyst view
Consensus: hold
Hold
Price target (mean) 23.75 +3455.4% upside
Now 0.668
- Target (low)
- 15.00
- Target (mean)
- 23.75
- Target (high)
- 57.00
Ratings (0m) 9 1 buy · 8 hold · 0 sell
- Strong buy1
- Buy0
- Hold8
- Sell0
- Strong sell0
Next earnings
Feb 11, 2025
Expected Feb 11, 2025. Consensus EPS estimate -0.40.
Financials — quick view
SITC Revenue — quarterly 8.56M
SITC Net income — quarterly -5.39M
SITC EPS — quarterly -0.10
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 11, 2025 | Dec 1, 2024 | 0.32 | — | — | — |
| Oct 30, 2024 | Sep 1, 2024 | 0.87 | 6.07 | +5.20 | +597.70% |
| Jul 30, 2024 | Jun 1, 2024 | 0.96 | 1.08 | +0.12 | +12.50% |
| Jul 30, 2024 | Jun 1, 2024 | 0.96 | 4.44 | +3.48 | +362.50% |
| Apr 30, 2024 | Mar 1, 2024 | 0.96 | -0.52 | -1.48 | -154.17% |
| Apr 30, 2024 | Mar 1, 2024 | 0.96 | 1.12 | +0.16 | +16.67% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 9, 2024 | Citigroup | main | Neutral | Neutral |
| Nov 4, 2024 | Piper Sandler | main | Overweight | Overweight |
| Aug 28, 2024 | Truist Securities | main | Hold | Hold |
| Aug 28, 2024 | Wells Fargo | main | Overweight | Overweight |
| Jul 31, 2024 | Piper Sandler | main | Overweight | Overweight |
| May 28, 2024 | Wells Fargo | main | Overweight | Overweight |
About SITE Centers Corp.
SITE Centers is an owner and manager of open-air shopping centers located in suburban, high household income communities. The Company is a self-administered and self-managed REIT operating as a fully integrated real estate company, and is publicly traded on the New York Stock Exchange under the ticker symbol SITC.
- Sector
- Real Estate
- Industry
- REIT - Retail
- Country
- United States
- Website
- sitecenters.com
News
MiNK Therapeutics New Data Highlights Its Off-the-Shelf iNKT Cell Therapy Targets Two Key Mechanisms of Tumor Resistance Presented at the Society of Immunotherapy of Cancer (SITC 2026) 
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer) 
Obsidian Therapeutics to Present Updated Amsoki-cel Efficacy and Pooled Safety Data in Advanced Melanoma at SITC 2026 Annual Meeting 
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026 
Candel Therapeutics Presents SITC 2026 Data Highlighting Systemic Immune Activation and Survival Outcomes Across Clinical-Stage Portfolio 
IMUNON Presents New Translational Data at SITC 2026 Demonstrating How IMNN-001 Activates and Sustains Anti-Tumor T-Cell Immunity in Advanced Ovarian Cancer 
Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026 
Why Cloudflare Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket 
BriaCell and BriaPro to Present Preclinical Anti-Cancer Activity and Immunotherapy Findings at SITC 2026 
MiNK Therapeutics to Report Third Quarter 2026 Results and Outline Progress in Randomized Clinical Development and Scalable iNKT Cell Therapy
Your note
Sign in to keep a note on SITC — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ABRAHAM LINDA BOLAND | Director | Stock Award(Grant) | Aug 14, 2024 | 46,298 |
| AHERN TERRANCE R | Director | Stock Award(Grant) | Aug 14, 2024 | 111,345 |
| DEFLORIO JANE E | Director | Stock Award(Grant) | May 14, 2024 | 57,158 |
| FENNERTY CONOR | Chief Financial Officer | Stock Award(Grant) | Mar 3, 2024 | 190,243 |
| LUKES DAVID R | Chief Executive Officer | Stock Award(Grant) | Mar 3, 2024 | 1,494,280 |
| MACFARLANE VICTOR BOLDT | Director | Stock Award(Grant) | May 14, 2024 | 7,115 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 16.55% | 8,679,211 | 132.79M | Sep 29, 2024 |
| FMR, LLC | 14.83% | 7,777,956 | 119.00M | Sep 29, 2024 |
| Vanguard Group Inc | 12.63% | 6,620,847 | 101.30M | Sep 29, 2024 |
| State Street Corporation | 5.23% | 2,743,657 | 41.98M | Sep 29, 2024 |
| Balyasny Asset Management LLC | 2.61% | 1,370,981 | 20.98M | Sep 29, 2024 |
| Morgan Stanley | 2.38% | 1,247,952 | 19.09M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Core S&P Smallcap ETF | 5.73% | 3,003,784 | 45.96M | Oct 30, 2024 |
| Vanguard Specialized-Real Estate Index Fund | 3.60% | 1,886,307 | 28.86M | Jul 30, 2024 |
| Fidelity Small Cap Value Fund | 2.47% | 1,293,750 | 19.79M | Aug 30, 2024 |
| iShares Russell 2000 ETF | 2.43% | 1,276,664 | 19.53M | Oct 30, 2024 |
| Vanguard Total Stock Market Index Fund | 2.17% | 1,140,269 | 17.45M | Sep 29, 2024 |
| Vanguard Small-Cap Index Fund | 1.75% | 919,361 | 14.07M | Sep 29, 2024 |